Prevention and management of adverse events related to regorafenib

Supportive Care in Cancer

Volumn 22, Issue 3, 2014, Pages 837-846

  De Wit, Mieke ^a   Boers Doets, Christine B ^b   Saettini, Alessandra ^c   Vermeersch, Kristina ^a   De Juan, Carmen Roncero ^d   Ouwerkerk, Jan ^b   Raynard, See See ^e   Bazin, Ashley ^f   Cremolini, Chiara ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e CROSS CANCER INSTITUTE   (Canada)

^f ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Adverse events; Fatigue; Hand foot skin reaction; Hypertension; Regorafenib; Supportive management

Indexed keywords

REGORAFENIB;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; DESQUAMATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG ERUPTION; FATIGUE; FOOT DISEASE; HAND DISEASE; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; LIVER DISEASE; PATIENT EDUCATION; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; STOMATITIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EXANTHEMA; FATIGUE; FOOT; GASTROINTESTINAL STROMAL TUMORS; HAND; HUMANS; HYPERTENSION; PHENYLUREA COMPOUNDS; PYRIDINES;

EID: 84895880965     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2085-z     Document Type: Review

References (25)

1. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch K-H, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255
2. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658-2667
3. European Medicines Agency (2013) Summary of opinion (initial authorisation): Stivarga regorafenib. EMA, London
4. US Food and Drug Administration (2012) Drugs: regorafenib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm321378.htm. Accessed 17 Sept 2013
5. PrStivarga. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2013- stivarga-157970-eng.php. Accessed 17 Sept 2013
6. US Food and Drug Administration (2013) FDA news release: FDA approves Stivarga for advanced gastrointestinal stromal tumors. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm340958.htm. Accessed 17 Sept 2013
7. Bayer Pharma AG (2013) Stivarga 40 mg film-coated tablets. Summary of product characteristics. Bayer, Berlin
8. ClinicalTrials.gov (2013) Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy. http://clinicaltrials.gov/show/NCT01103323. Accessed 17 Sept 2013
9. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, original article and supplementary appendix
10. ClinicalTrials.gov (2013) Study of regorafenib as a 3rd-line of beyond treatment for gastrointestinal stromal tumors (GIST) (GRID). http://clinicaltrials.gov/show/NCT01271712. Accessed 17 Sept 2013
11. Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302, original article and supplementary appendix
12. ClinicalTrials.gov (2013) Regorafenib in subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN). http://clinicaltrials.gov/show/NCT01538680. Accessed 17 Sept 2013
13. US Department of Health and Human Services (2010) Common terminology criteria for adverse events (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/. Accessed 17 Sept 2013
14. Wood LS, Lemont H, Jatoi A, Lacouture ME, Robert C, Keating K, Anderson R (2010) Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Commun Oncol 7:23-29
15. Grothey A, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Wagner A, Laurent D, Cupit L (2012) Time course of regorafenib-associated adverse events in the phase III CORRECTstudy. J Clin Oncol 30(Suppl 34):467
16. Aklilu M, Anderson RT, Keating KN, O'Leary JJ (2008) Patient interviews on hand-foot syndrome: symptom assessment and impact on quality of life. J Clin Oncol 26(Suppl 15):20713
17. Khayyam KU, Imam F, Sharma M, Pillai KK, Behera D (2010) Pyrazinamide-induced maculopapular rash. Indian J Dermatol 55:384-386
18. McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI (1998) Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 34:484-490 (Pubitemid 28546862)
19. Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920-924 (Pubitemid 27382038)
20. Ewer MS (2011) Chemotherapy-related cardiac safety. Research review speaker series. http://www.researchreview.co.nz/getmedia/8cc9638a-4d34-4761- a402-32d70b4758bf/ss-ewer.pdf.aspx. Accessed 17 Sept 2013
21. Ewer MS, Ewer SM (2011) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7:564-575
22. Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J Manage 34:1102-1111
23. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12:4-10
24. Cheville AL, Kollasch J, Vandenberg J, Shen T, Grothey A, Gamble G, Basford JR (2013) A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manag 45:811-821
25. Lin KY, Shun SC, Lai YH, Liang JT, Tsauo JY (2013) Comparison of the effects of a supervised exercise program and usual care in patients with colorectal cancer undergoing chemotherapy. Cancer Nurs. doi:10.1097/NCC. 0b013e3182791097